Skip to content

Provention Bio initiates Phase 2b PROACTIVE study of PRV-015

August 31, 2020

Provention Bio (PRVB +1.1%) announced the initiation of the Phase 2b PROACTIVE study of PRV-015, an anti-interleukin-15 monoclonal antibody, in adult celiac patients not responding to a gluten-free diet, a condition known as ‘Non-Responsive Celiac Disease‘.

Provention is developing PRV-015 under its 2018 collaboration with Amgen.

“PRV-015 has the potential to be the first-ever approved therapeutic for celiac disease.” stated Francisco Leon, MD, PhD, Chief Scientific Officer and Co-Founder.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: